RECORD // Company
Silexion Therapeutics Corp Formerly: Biomotion Sciences
Built 2026-11-22T01:26:08Z from public sources · JSON · Open the company profile
Records for this company (1 joined by official identifier) Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.
SEC EDGAR (1) 3 VALUES · 10-Q · EACH LINKS TO ITS FILING
Latest quarter Latest report: 10-Q for the period ended 2026-09-30 , filed 2026-11-12 · accession 0001178913-26-005201
Negative as reported in the filing.
Not in this report's XBRL: Revenue.
Values as filed in XBRL (SEC company facts ); quarterly values are the filer's 3-month figures, never derived.
Identifiers
SEC CIK 0002022416
Ticker SLXN
CUSIP G1281K130
Record ID sx:sec:0002022416 OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA
Open in Open in… Analyst estimates and earnings Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
24 FACTS · EACH LINKS TO ITS FILING
Facts Fact Value As of Source Retrieved Report SEC entity type operating 2026-11-19 SEC EDGAR company profile 2026-11-22 01:26 UTC Report an error SIC industry 2836 Biological Products, (No Diagnostic Substances) 2026-11-19 SEC EDGAR company profile 2026-11-22 01:26 UTC Report an error State of incorporation E9 2026-11-19 SEC EDGAR company profile 2026-11-22 01:26 UTC Report an error Fiscal year end (MMDD) 1231 2026-11-19 SEC EDGAR company profile 2026-11-22 01:26 UTC Report an error Business address 12 ABBA HILLEL ROAD, RAMAT GAN, L3, 5250606 2026-11-19 SEC EDGAR company profile 2026-11-22 01:26 UTC Report an error Exchanges Nasdaq, Nasdaq 2026-11-19 SEC EDGAR company profile 2026-11-22 01:26 UTC Report an error Net income (loss) (fiscal year ended 2025-12-31) $-11,912,000 2025-12-31 10-K, XBRL NetIncomeLoss 2026-11-22 01:26 UTC Report an error Total assets (at 2025-12-31) $7,215,000 2025-12-31 10-K, XBRL Assets 2026-11-22 01:26 UTC Report an error Stockholders' equity (at 2025-12-31) $2,603,000 2025-12-31 10-K, XBRL StockholdersEquity 2026-11-22 01:26 UTC Report an error Cash and cash equivalents (at 2025-12-31) $5,991,000 2025-12-31 10-K, XBRL CashAndCashEquivalentsAtCarryingValue 2026-11-22 01:26 UTC Report an error Operating cash flow (fiscal year ended 2025-12-31) $-10,819,000 2025-12-31 10-K, XBRL NetCashProvidedByUsedInOperatingActivities 2026-11-22 01:26 UTC Report an error Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) $9,000 2025-12-31 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment 2026-11-22 01:26 UTC Report an error Operating lease liabilities (at 2025-12-31) $468,000 2025-12-31 10-K, XBRL OperatingLeaseLiability 2026-11-22 01:26 UTC Report an error Form D total offering amount (D filed 2025-08-11) $3,597,662 2025-08-11 D 2026-11-22 01:26 UTC Report an error Form D total amount sold (D filed 2025-08-11) $3,597,662 2025-08-11 D 2026-11-22 01:26 UTC Report an error Form D industry group Biotechnology 2025-08-11 D 2026-11-22 01:26 UTC Report an error Form D revenue range No Revenues 2025-08-11 D 2026-11-22 01:26 UTC Report an error Form D date of first sale 2025-08-01 2025-08-11 D 2026-11-22 01:26 UTC Report an error 8-K Item 8.01, Other Events (filed 2026-11-19) Outcome of Nasdaq Hearings Panel; Continued Listing On November 18, 2026, Silexion Therapeutics Corp. (the “Company”) received a favorable decision from a Nasdaq Hearings Panel granting the Company’s request for continued listing on the Nasdaq Capital Market, subject to the conditions described below. The decision followed the Company’s appeal of Nasdaq’s August 18, 2026 delisting determination relating to the Company’s non-compliance with the $2.5 million minimum shareholders’ equity requirement and also addressed the Company’s non-compliance with Nasdaq’s $1.00 minimum bid price requirement. In its final form, the Panel’s decision requires the Company to: (i) by December 4, 2026, complete… 2026-11-19 SEC EDGAR 8-K 0001178913-26-005294 (text as filed, excerpt) 2026-11-22 01:26 UTC Report an error 8-K Item 2.02 (filed 2026-11-16) Results of Operations and Financial Condition. On November 13, 2026, Silexion Therapeutics Corp issued a press release announcing its financial results for the third quarter and nine months ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference into this Item 2.02. The information contained in this Item 2.02 and Exhibit 99.1 hereto shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor will such information be deemed incorporated by reference in any filing under the Securities Act… 2026-11-16 SEC EDGAR 8-K 0001178913-26-005216 (text as filed, excerpt) 2026-11-22 01:26 UTC Report an error 8-K Item 3.03 (filed 2026-11-12) Material Modification to Rights of Security Holders. In connection with its previously-announced 1-for-24 reverse share split of all of its issued and outstanding, and authorized but unissued, ordinary shares (the “Reverse Share Split”) described in Item 5.03 below, on November 11, 2026, Silexion Therapeutics Corp (the “Company”) issued a notice (the “Warrant Adjustment Notice”) to holders of its public warrants and private warrants to purchase the Company’s ordinary shares (the “Warrants”). In the Warrant Adjustment Notice, the Company notified Warrant holders that the Company has made the following adjustments to its outstanding Warrants, effective after the close of trading on November… 2026-11-12 SEC EDGAR 8-K 0001178913-26-005191 (text as filed, excerpt) 2026-11-22 01:26 UTC Report an error 8-K Item 5.03 (filed 2026-11-12) Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. As previously reported by the Company in its Current Report on Form 8-K filed with the Securities and Exchange Commission on October 26, 2026, at the extraordinary general meeting of the Company originally held on October 19, 2026 and reconvened on October 26, 2026, the Company’s shareholders approved the Reverse Share Split (as described in Item 3.03 above), at the 1-for-24 ratio determined by the Company’s Board of Directors. On November 10, 2026, the Company’s Board of Directors, acting pursuant to that approval by the Company’s shareholders, effected the Reverse Share Split following the close of trading on the… 2026-11-12 SEC EDGAR 8-K 0001178913-26-005191 (text as filed, excerpt) 2026-11-22 01:26 UTC Report an error 8-K Item 8.01 (filed 2026-11-12) Other Events. The information set forth in Items 3.03 and 5.03 is hereby incorporated by reference into this Item 8.01. 2026-11-12 SEC EDGAR 8-K 0001178913-26-005191 (text as filed, excerpt) 2026-11-22 01:26 UTC Report an error 8-K Item 8.01, Other Events (filed 2026-11-09) Further to its previous reports, as well as the approval of its shareholders received on October 26, 2026, on November 9, 2026, Silexion Therapeutics Corp, a Cayman Islands exempted company (“Silexion” or the “Company”) issued a press release announcing a prospective 1-for-24 reverse share split of all of its issued and outstanding, and authorized but unissued, ordinary shares. The reverse share split will become effective after the close of the market on November 10, 2026, and the Company’s ordinary shares will begin trading on a reverse split-adjusted basis on the Nasdaq Capital Market at the open of the market on November 11, 2026. The ticker symbol for the ordinary shares will remain… 2026-11-09 SEC EDGAR 8-K 0001178913-26-005089 (text as filed, excerpt) 2026-11-22 01:26 UTC Report an error
EVERY DATED RECORD, NEWEST FIRST
Timeline All (25) Filing (25)
Gaps Court records: not covered yet (expected 11-19). No EIN on the SEC filing, so no Form 990 lookup SEC 13F holders: no 13F holdings for this CUSIP in period 2026-06-30 USAspending: no recipient whose SAM legal name and address match this SEC filer Sources SEC EDGAR: checked · 2026-11-22T01:26:08Z Propublica 990: checked, nothing found · 2026-11-22T01:26:09Z SEC 13F holdings: checked · 2026-11-22T01:26:09Z USAspending: checked, nothing found · 2026-11-22T01:26:10Z CC BY 4.0 -- credit Seraphix Systems.
Use this record Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key ; send Authorization: Bearer <key>.